Investigational drug · Phase 3
XY0206
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukemia With FLT3/ITD Mutation.
Phase 3Last checked: Nov 19, 2026Latest source record: May 26, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "XY0206"
First trial start
2023
Jun 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XY0206", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukemia With FLT3/ITD Mutation
Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "XY0206" as an intervention, largest first.
- A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)Pivotal-lookingNot yet recruiting
Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
NCT05876832 · 312 participants (planned) · Start Jun 15, 2023 · Primary completion Jul 1, 2027
Drug: XY0206; Salvage Chemotherapy · For: Acute Myeloid Leukemia With FLT3/ITD Mutation
- A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid LeukemiaStatus unknown
Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
NCT04471064 · 60 participants (planned) · Start Sep 15, 2020 · Primary completion Feb 2024
Drug: XY0206 · For: Acute Myeloid Leukemia
Sites: Tianjin, China
- A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy ParticipantsRecruiting
Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
NCT07162116 · 45 participants (planned) · Start Jul 6, 2025 · Primary completion Dec 1, 2025
Drug: XY0206; Moxifloxacin (400 mg) · For: Acute Myeloid Leukemia With FLT3/ITD Mutation
Sites: Zibo, China
Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
NCT03658070 · 34 participants (planned) · Start Dec 19, 2018 · Primary completion Dec 2020
Drug: XY0206 · For: Advanced or Metastatic Solid Tumours
Sites: Beijing, China; Haikou, China; Shijiazhuang, China · 4 sites in all
Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
NCT06823232 · 6 participants · Start Nov 6, 2024 · Primary completion Dec 5, 2024
Drug: [14C]XY0206 · For: Metabolism of Radioactive Substances
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- XY0206: A promising sunitinib-derived FLT3 inhibitor targeting therapy-resistant acute myeloid leukemia.
Yang Y · J Clin Invest 2026
- XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia.
Shen L, Yang Y, Xu C, et al. · J Clin Invest 2026
- Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
Song L, Wei X, Zhai Z, et al. · Eur J Haematol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.